Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsShares IssuedWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Long-Term Debt Repayments (2017 - 2021)

Historic Long-Term Debt Repayments for Protalix BioTherapeutics (PLX) over the last 3 years, with Q4 2021 value amounting to $4.0 million.

  • Protalix BioTherapeutics' Long-Term Debt Repayments changed N/A to $4.0 million in Q4 2021 from the same period last year, while for Dec 2024 it was $26.0 million, marking a year-over-year change of. This contributed to the annual value of $20.4 million for FY2024, which is N/A changed from last year.
  • Per Protalix BioTherapeutics' latest filing, its Long-Term Debt Repayments stood at $4.0 million for Q4 2021.
  • Protalix BioTherapeutics' Long-Term Debt Repayments' 5-year high stood at $21.9 million during Q3 2021, with a 5-year trough of $11668.0 in Q1 2018.
  • Its 3-year average for Long-Term Debt Repayments is $6.5 million, with a median of $4.2 million in 2017.
  • The largest annual percentage gain for Protalix BioTherapeutics' Long-Term Debt Repayments in the last 5 years was 1193.23% (2018), contrasted with its biggest fall of 9982.65% (2018).
  • Protalix BioTherapeutics' Long-Term Debt Repayments (Quarter) stood at $4.2 million in 2017, then rose by 11.93% to $4.7 million in 2018, then fell by 14.65% to $4.0 million in 2021.
  • Its Long-Term Debt Repayments stands at $4.0 million for Q4 2021, versus $21.9 million for Q3 2021 and $4.1 million for Q1 2021.